ELI LILLY & Co (LLY) vs REGENERON PHARMACEUTICALS, INC. (REGN)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | LLY | REGN |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.18B | $14.34B |
| Revenue growth (YoY) | ▲ 44.7% | ▲ 1.0% |
| Net income | $20.64B | $4.5B |
| Gross margin | 83.0% | — |
| Diluted EPS | $22.95 | $41.48 |
| Insider net (6 mo) | −31.3K sh • 5 sells • 0 buys | +2.3K sh • 7 sells • 0 buys |
| Institutional owners | 51 | 45 |
| Institutional value held | $533.23B | $38.9B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Jan 11, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
About REGENERON PHARMACEUTICALS, INC. (REGN)
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular… Read more →
Source: SEC EDGAR.